Repligen Q3 revenue $178.2M (+89% YoY); raises FY 2021 revenue guidance to $655-665M

REPLIGEN CORP

2021-Q3 EPS reported $1.74 revenue$484,013,000

Revenue hit a record $178.2M in Q3 2021, up 89% YoY as reported and 77% organically.
GAAP EPS of $0.58, Adjusted EPS of $0.78; GAAP operating margin rose to 25.4%.
FY 2021 revenue guidance raised to $655-665M (prior $625-645M); adjusted EPS guidance raised to $2.86-$2.91.
Completed acquisition of affinity ligands innovator Avitide Inc. during the quarter.
COVID programs contributed 27% of Q3 revenue; base business grew 49% YoY.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.